Rallybio Initiates Dosing In RLYB116 Phase 1 Confirmatory Study
ReutersJun 12, 2025 12:20 PM
June 12 (Reuters) - Rallybio Corp RLYB.O:
RALLYBIO INITIATES DOSING IN RLYB116 PHASE 1 CONFIRMATORY PHARMACOKINETIC/PHARMACODYNAMIC STUDY
RALLYBIO CORP - DATA READOUTS EXPECTED FROM COHORT 1 IN 3Q 2025 AND COHORT 2 IN 4Q 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
SK Hynix Margin Tops TSMC as Micron Misses Out on Nvidia Orders, Is the HBM Sector Facing a Shake-Up?
Samsung, which lagged behind during the HBM3 era, has returned to the arena, while Micron, once a frontrunner, missed out on Nvidia’s orders. Is a reshuffle imminent in the HBM sector?TradingKey
19 hours ago
Best AI Tools for Stock Analysis in 2026 to Boost Your Investment Portfolio
As Artificial Intelligence (AI) continues to enhance everyday decision-making, these tools will allow us to leverage artificial intelligence to analyse stocks and optimise our investment portfolio.TradingKey
23 hours ago
Strategy Defies DAT Sell-Off, Doubles Down Amid Leverage Woes
MicroStrategy acquired over 1,000 additional Bitcoins last week, with Michael Saylor stating the company will purchase Bitcoin every quarter moving forward.TradingKey
Wed, Feb 11
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalanceTradingKey
Wed, Feb 11
